If so, how do you determine which of the lesions constitutes the "dominant" lesion to boost?
Alternatively, do you treat all noted lesions with SIB, or do you avoid SIB altogether in this case where a dominant intraprostatic lesion is not easily identifiable?
Outstanding response. My practice is similar, also...